HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD. Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Share Price
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.68 CNY | +0.71% |
|
-1.06% | -6.79% |
| Sales 2024 * | 1.36B 188M 14.86B | Sales 2025 * | 1.8B 248M 19.56B | Capitalization | 6.56B 904M 71.42B |
|---|---|---|---|---|---|
| Net income 2024 * | 375M 51.65M 4.08B | Net income 2025 * | 500M 68.86M 5.44B | EV / Sales 2024 * | 4.81 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.65 x |
| P/E ratio 2024 * |
17.6
x | P/E ratio 2025 * |
13.2
x | Employees | 1,747 |
| Yield 2024 * |
1.87% | Yield 2025 * |
2.51% | Free-Float | 50.47% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.71% | ||
| 1 week | -1.06% | ||
| Current month | -1.92% | ||
| 1 month | -4.74% | ||
| 3 months | -14.84% | ||
| 6 months | -1.40% | ||
| Current year | -6.79% |
1 week
59.52
62.11
1 month
59.0064.85
Current year
51.0177.78
1 year
51.0177.78
3 years
51.01120.00
5 years
51.01120.00
10 years
51.01120.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jin Fang Lou
CEO | Chief Executive Officer | 56 | 31/07/15 |
Dong Bo Yan
DFI | Director of Finance/CFO | 33 | 31/01/23 |
| 43 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hui Lin Li
BRD | Director/Board Member | 67 | 25/06/19 |
Yong Zhou Hu
BRD | Director/Board Member | 74 | 25/06/19 |
Jin Fang Lou
CEO | Chief Executive Officer | 56 | 31/07/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 60.68 | +0.71% | 838,688 |
| 19/06/24 | 60.25 | +0.02% | 613,855 |
| 18/06/24 | 60.24 | -1.44% | 756,451 |
| 17/06/24 | 61.12 | +1.09% | 653,499 |
| 14/06/24 | 60.46 | -1.42% | 622,105 |
End-of-day quote Shenzhen S.E., June 19, 2024
More quotes
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a China-based company mainly engaged in comprehensive pharmaceutical technology research and development (R&D). The services provided by the Company mainly include entrusted R&D of pharmaceutical technology and transformation of independent R&D technological achievements. The entrusted R&D business provides integrated pharmaceutical R&D services such as pharmaceutical research, clinical trial and registration application for major pharmaceutical enterprises and pharmaceutical R&D investment enterprises. The transformation business of independent R&D technological achievements is based on the independent project research and development of drug R&D platform, and actively promote the transformation of independent R&D technological achievements after obtaining phased R&D achievements.
Calendar
07/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
60.68
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.79% | 904M | |
| +35.14% | 51.51B | |
| -7.43% | 39.03B | |
| +35.88% | 38.91B | |
| -10.62% | 26.68B | |
| +11.63% | 26.13B | |
| -17.77% | 19.91B | |
| +40.52% | 13.71B | |
| +30.70% | 12.38B | |
| -3.41% | 11.74B |
- Stock Market
- Equities
- 301096 Stock
